Using sCD8 as a new biomarker for pancreatic cancer detection
The Diagnostic and Survival Predictive Value of Peripheral Serum Soluble CD58 (sCD5858) in Pancreatic Cancer Patients
This study is testing if new blood markers can help find pancreatic cancer earlier and track its progress in patients and healthy volunteers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT05500027 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of soluble CD58 (sCD58) and TGFβ1 as novel serum biomarkers for the early detection and monitoring of pancreatic cancer. The study will involve healthy volunteers and patients with various stages of pancreatic cancer, as well as other related conditions, to assess the levels of these biomarkers before and after surgical interventions. By understanding the relationship between these biomarkers and pancreatic cancer progression, the study seeks to improve diagnostic accuracy and patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with stage I-IV pancreatic cancer, as well as those with related conditions such as chronic pancreatitis and autoimmune diseases.
Not a fit: Patients who are under 18 or over 85 years old, or those who refuse to participate, will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate detection of pancreatic cancer, potentially improving survival rates.
How similar studies have performed: While the use of biomarkers for pancreatic cancer detection is an established area of research, the specific approach of using sCD58 and TGFβ1 as diagnostic tools is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy volunteers * Stage I-IV pancreatic cancer patients with pathological diagnosis * Pancreatic cancer patients before and 1 week after surgery * Pancreatic cancer patients before and 1 week after bile drainage * IPMN patients with pathological diagnosis before and 1 week after surgery * MCN patients with pathological diagnosis before and 1 week after surgery * SPN patients with pathological diagnosis before and 1 week after surgery * PNEN patients with pathological diagnosis before and 1 week after surgery * Chronic pancreatitis patients with pathological diagnosis * Cholecystitis patients meeting clinical criteria * Cholangitis patients meeting clinical criteria * Autoimmune diseases meeting clinical criteria Exclusion Criteria: * Refusal to participate * Age less than 18-year old and over 85-year old
Where this trial is running
Beijing, Beijing
- Peking Union Medical College Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Study coordinator: Qiaofei Liu, MD
- Email: qfliu@aliyun.com
- Phone: 15201693370
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.